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Prevention of malignant hyperthermia (MH) requires an understanding of RYR1 variant 
pathogenicity to assess the risk of exposure to triggering agents. Personalized medicine, 
especially secondary findings and eventually genomic screening, will contribute toward this 
goal. 
Methods 
We specified ACMG/AMP criteria for variant interpretation for RYR1 and MH. Proposed rules 
were piloted on 84 variants. We applied quantitative evidence calibration for several criteria 
using likelihood ratios based on the Bayesian framework. 
Results 
Seven ACMG/AMP criteria were adopted without changes, ten were adopted with RYR1-
specific modifications, and nine were dropped. The in silico (PP3 and BP4) and hot spot criteria 
(PM1) were evaluated quantitatively. REVEL gave an OR of 23:1 for PP3 and 16:1 for BP4 using 
trichotomized cut-offs of >0.85 (pathogenic) and <0.5 (benign). The PM1 hotspot criterion had 
an OR of 24:1. PP3 and PM1 were implemented at moderate strength. Applying the revised 
ACMG criteria to 44 recognized MH variants, 30 were assessed as pathogenic, 12 as likely 
pathogenic, and two as VUS. 
Conclusion 
Curation of these variants will facilitate interpretation of RYR1/MH genomic testing results, 
which is especially important for secondary findings analyses. Our approach to quantitatively 
calibrating criteria are generalizable to other variant curation expert panels.  
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INTRODUCTION 
Malignant hyperthermia susceptibility (MHS) is a potentially lethal inherited disorder of skeletal 
muscle calcium signaling, predisposing individuals to a hypermetabolic reaction triggered by 
exposure to inhalational anesthetics or depolarizing muscle relaxants such as succinylcholine.1,2 
Inheritance of MHS is predominantly autosomal dominant, although autosomal recessive 
inheritance has been reported3 and non-Mendelian models proposed.4 Variants in RYR1 
(MIM:180901; MHS1, MIM:145600) and CACNA1S (MIM:114208; MHS5, MIM:601887) have 
been identified as associated with MH, and both genes are in the American College of Medical 
Genetics and Genomics (ACMG) return of secondary findings recommendations.5,6 RYR1 
variants account for ~76% of MH events while ~1%7 are attributable to CACNA1S and <1% are 
attributable to STAC3 (MIM:615521; Bailey-Bloch myopathy, MIM:255995). Four additional loci 
have been mapped (MHS2, MIM:154275; MHS3, MIM:154276; MHS4, MIM:600467; MHS6, 
MIM:601888). RYR1 has a complex gene-to-phenotype relationship, being associated with 
several apparently distinct disorders and both autosomal dominant and autosomal recessive 
inheritance. Overlapping conditions include central core disease (CCD, MIM:117000) and King-
Denborough syndrome (MIM:145600) and individuals with these disorders may be at risk for 
MH. Generally, these disorders result from monoallelic RYR1 variants while biallelic variants 
cause other myopathies including neuromuscular disease with uniform type 1 fiber 
(MIM:117000) and minicore myopathy with external ophthalmoplegia (MIM:255320), however, 
this correlation is evolving.8 
Interpretation of RYR1 variants is complicated by variable expressivity, reduced penetrance and 
high alleleic heterogeneity. While the European Malignant Hyperthermia Group (EMHG; 
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http://www.emhg.org/home/) has assessed 48 RYR1 variants as diagnostic of MHS, over 165 
additional variants have been reported as disease mutations/pathogenic/likely pathogenic for 
MH in the literature and databases including HGMD9,10 and ClinVar.13 While the ACMG/AMP 
guidelines provided general criteria that can be used to assess variants, many of the criteria 
require adaptation to be accurately applied. As part of ClinGen, we convened an RYR1-related 
Malignant Hyperthermia variant curation expert panel 
(https://clinicalgenome.org/affiliation/50038/) to adapt the general ACMG/AMP pathogenicity 
guidelines to RYR1/MH, with gene-specific recommendations, to improve interpretation of 
RYR1 variants. 
We first reviewed each ACMG/AMP criterion to determine their applicability to RYR1/MH and 
then adapted them with gene/disease specific guidelines, if appropriate. We piloted these 
guidelines on 84 variants – 44 variants from the EMHG list of diagnostic variants and 40 variants 
with MH pathogenicity assertions in ClinVar. 
METHODS 
ClinGen’s RYR1/MH Expert Panel 
The RYR1/MH expert panel (EP) is composed of clinical molecular geneticists, clinical 
geneticists, anesthesiologists, biochemists, and physiologists to provide a balance of expertise 
relevant to RYR1 variant interpretation. The RYR1/MH EP met monthly via conference calls over 
a two-year period. 
Evaluation and Adaptation of the ACMG Pathogenicity Guidelines 
The general ACMG/AMP pathogenicity guidelines were evaluated for relevance to RYR1/MH 
and criteria that were not relevant were dropped. ClinGen-recommended amendments to the 
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ACMG/AMP criteria were incorporated when applicable. Lastly, applicable criteria were further 
assessed to determine if gene-specific recommendations were warranted. Proposed changes 
were discussed amongst the full EP by means of emails and conference calls to develop 
consensus. Draft rules were piloted on a subset of RYR1 variants representing the EMHG 
diagnostic variant list. Individual panel members scored variants using the draft guidelines and 
variant interpretations were presented to the full panel. Areas of disagreement were used to 
refine the draft guidelines. 
Data Collection Methods 
Population data for each variant were ascertained from gnomAD.11 REVEL scores were used for 
bioinformatic predictions for single nucleotide variants (SNVs).12 The literature was searched for 
data relevant to each variant including case information and functional data. For case 
information, the number of unrelated probands with either a personal or family history of an 
MH event was recorded (see supplemental information). Care was taken to avoid double 
counting cases reported multiple times. Reports were examined for instances of de novo 
inheritance and/or segregation. 
Pathogenicity Assessment 
Revised ACMG/AMP criteria were used to assess 44 EMHG MH diagnostic variants. Four of 48 
EMHG variants were excluded because they were only associated with RYR1-related 
myopathies and not MH. An additional 40 ClinVar RYR1 variants were also assessed. Individual 
criteria were weighted based on available evidence and then weighted criteria were combined 
using the Bayesian framework for variant scoring.13 
RESULTS AND DISCUSSION 
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The ACMG/AMP guidelines are generic and broadly useful for all genes and disorders. These 
generic rules may over- or under-estimate evidence for any specific gene and must be adapted 
for specific implementations. As an EP, we suggest guidelines to be used/dropped, guidelines to 
be refined, and weight adjustments where appropriate. Summary of revised guidelines are in 
Table 1 and a full description of the revised guidelines is in Table S1 with gene/disease specific 
adaptations highlighted below. 
Criteria Dropped for MH/RYR1: PVS1/PM3/PM4/PP2/PP4/BS4/BP1/BP3/BP5 
These criteria were dropped based on the biology of MH/RYR1. See supplemental information 
for details. 
Criteria Used According to General Guidelines: PS1/PS2/PM5/PM6/PP1/BP2/BP7 
These criteria were retained in the RYR1/MH-specific guidelines including adaptations as 
recommended by the Clingen Sequence Variant Interpretation (SVI) committee (PS2/PM6, 
weighting of de novo observations, 
https://clinicalgenome.org/site/assets/files/3461/svi_proposal_for_de_novo_criteria_v1_0.pdf
) and the Cardiomyopathy EP (PP1, weighting segregation events in families).14 We made 
further modifications to the ACMG/AMP criteria, which may not be specific to RYR1/MH. The 
PS1 (same amino acid change, different nucleotide change) and PM5 (different amino acid 
change, same codon) criteria were modified such that in order to use either of them, one 
variant should reach an assessment of pathogenic based on criteria other than PS1 and PM5. 
Then, PS1 or PM5 may be used for a second variant. Furthermore, for PM5, we added a 
requirement that the Grantham score difference compared to reference of the new variant 
must be greater than that for the previously identified pathogenic variant compared to 
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reference. For criterion BP2 (evidence against pathogenicity based on presence of known 
pathogenic variant) it is suggested that only variants identified in cis with the variant under 
review be considered. Because the occurrence of biallelic pathogenic RYR1 variants has been 
described in MHS,3,15 two variants in trans is not considered evidence against pathogenicity for 
RYR1/MH. Finally, BP7 concerns synonymous variants without predicted effects on splicing. As 
RYR1/MH primarily results from missense alterations, BP7 is used as recommended. 
Criteria Specified for RYR1/MH: BA1/BS1/PS4/PM2/BS2/PS3/BS3/PM1/PP3/BP4 
Allele Frequency Specificiations: BA1/BS1/PS4/PM2 
BA1 and BS1 use minor allele frequencies (MAF) in population datasets to support benign 
classification for common variants. The BA1 criterion is considered stand alone and was 
originally set to 0.05 (5%) MAF.16 It has been suggested that BA1 can be defined as the 
combined MAF for all pathogenic variants in the population for the gene/disease dyad with the 
understanding that any one variant should have a lower MAF than the combined total. To 
determine a gene/disease-specific cutoff for BA1, disease prevalence, penetrance, and gene 
contribution need to be considered. This can be estimated by the formula:
.14 The prevalence of MH (defining 
the disorder as MH, not MHS) in the population can be estimated using the frequency of MH 
events in individuals exposed to triggering agents. The frequency of events is as high as 
1/10,000 pediatric anesthesias.2 The rate of adult MH events seems lower than that of 
children17 but the underlying genetic risk is assumed to be the same. The gene contribution of 
RYR1 to MH is ~76% depending on ethnicity.7 Calculating thresholds for BA1 relies on an 
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accurate estimate of penetrance, which is very difficult to determine for MHS.18 In lieu of using 
an estimate for MHSpenetrance, we instead substituted a value of 1%, as it is a reasonable 
boundary between the penetrance of a Mendelian disorder variant and that of a risk allele. This 
value is nearly certain to be lower than the actual penetrance of MHS, but underestimating this 
value is conservative with respect to the outcome in that it will numerically raise BA1, which 
would lead to fewer variants being classified as benign based on this single criterion. Using 0.01 
to adjust our calculated BA1 allows for a BA1 MAF of 0.0038 (0.38%). 
In addition to a stand alone MAF (BA1), BS1 defines the MAF at which a variant is considered to 
have strong evidence against pathogenicity. The field has been moving to define BS1 based on 
the contribution of the most common pathogenic allele for a disorder. For RYR1/MH, we 
calculated BS1 considering the frequency of MH reactions in children (1/10,000) a value of 0.01 
substituted for penetrance (as explained above), and a maximum individual allele contribution 
of 16%.7 Correcting for alleles/person gives a BS1 value of 0.0008 (0.08%). 
While a high MAF of a variant in controls can be used to refute pathogenicity, criterion PM2 
gives weight for absence or very low frequency of a variant in control populations. Based on 
observations that the majority of possible RYR1 missense variants (~30,000 variants) are not 
represented in gnomAD (2,800 RYR1 missense variants) and many known pathogenic variants 
(assessed without the use of PM2) are present in gnomAD, it is unlikely that the absence of a 
variant in gnomAD is support for pathogenicity. While the absence or low frequency of a variant 
in gnomAD has little value alone, it is an important component of weighting the presence of a 
variant in affected individuals. PS4 takes into consideration the prevalence of the variant in 
affected individuals compared to controls. For RYR1/MH, we modified the PS4 criterion using a 
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point system, awarding 0.5 case points for each unrelated proband reported to have undergone 
an MH event and awarding an additional 0.5 case points for a positive in vitro contracture 
(IVCT) or caffeine-halthane contracture (CHCT) diagnostic test in either the proband or a 
variant-positive family member. The strength level of PS4 is based on odds ratios comparing 
total case points, an approximation of the total number of cases of MH investigated in the 
literature (3,000) and a MAF of 0.00006 for an allele with high coverage in the NFE population 
(approximately 7/113,000 alleles). When popmax frequency in gnomAD is >0.00006, cases can 
be counted and compared to alleles in the gnomAD population with the highest MAF by 
calculating an odds ratio (OR, MedCalcs online calculator 
(https://www.medcalc.org/calc/odds_ratio.php). Strength levels are awarded according to the 
following system: PS4 for ≥7 MH case points or an OR of 18.7; PS4_Mod for 2-6 MH cases points 
or an OR of 4.33; and PS4_Sup for one MH case point or an OR of 2.08. Every effort needs to be 
made to avoid double counting of cases reported in multiple studies. The Bayesian framework 
for the classification of variants using the ACMG/AMP criteria was used to set the OR value for 
each strength level.13 
Disease-Specific Phenotype: BS2 
The IVCT/CHCT diagnostic tests have low false negative rates19,20 and can be used to determine 
MHS status in individuals who carry RYR1 variants. A negative IVCT or CHCT result supports 
benign status. Two or more unrelated individuals with a negative result allow BS2 to be applied. 
One individual with a negative result allows BS2_Mod. 
Functional Assay Specifications: PS3/BS3 
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Functional characterization is a crucial determinant of the pathogenicity of RYR1 variants in the 
MH field.21 Within the ACMG/AMP guidelines, functional assay results are used for PS3 (well-
established in vitro or in vivo functional studies supportive of a damaging effect) and BS3 (well-
established in vitro or in vivo functional studies show no damaging effect on protein function or 
splicing). RYR1 is a homotetrameric calcium channel in the sarcoplasmic reticulum (SR) of 
skeletal muscle important in excitation-contraction coupling. Volatile anesthetics and 
depolarizing muscle relaxants can cause increased release of SR calcium in a dysfunctional RYR1 
channel resulting in MH. When considering functional assays for variant assessment it is 
desirable to identify assays that are closely related to the physiologic defect causative of 
disease. For RYR1/MH, assays that measure release of calcium in response to pharmacologic 
agents are considered good representations of the disease mechanism. Well-recognized assays 
include transfection of RYR1 cDNA into either HEK293 cells, CHO cells, or RYR1 knockout 
myotubes (dyspedic) followed by SR calcium release measurement in response to caffeine, 
halothane, voltage/potassium, or 4-chloro-m-cresol (4-CmC). A significant decrease in the EC50 
for the sensitivity of calcium release compared to wildtype RYR1, is considered evidence for 
pathogenicity. Multiple replicates for each variant within a single instance of the assay are 
necessary to determine significance of these values. Positive (pathogenic) and negative (benign) 
controls support that the assay categorizes the variants accurately. For the purpose of assessing 
RYR1 transfection studies to weight PS3, results are dichotomized into pathogenic EC50 values 
that are significantly decreased as compared to WT versus benign EC50 values that are not 
significantly decreased. For RYR1 pathogenicity assessment, the whole of prior published work 
(Figure 1, Table S2)22 allows us to consider transfection assays in HEK293 cells using 
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photometry/imaging to measure calcium release a well defined functional test. However, 
recommendations for increased stringency in analyses of functional data have recently been 
suggested.23 To determine the appropriate PS3 weight based on HEK293 transfection assays we 
have considered results published in the literature including results for a total of 35 variants 
assessed to be likely pathogenic or pathogenic (LP/P) without the use of functional data, and 
ten control variants including variants associated with CCD (8) and common variants (2). Of the 
35 LP/P variants, 29 have been shown to reduce the calcium release EC50 in response to RYR1 
agonsits. Five variants have shown discordant results across assays, and one variant has shown 
an EC50increase. Of the ten control variants, one variant has shown an EC50 reduction in 
response to agonist and nine variants have either shown no response to agonist (6) or a 
response similar to WT RYR1 (3). This set of variants suggests a likelihood ratio for an EC50 
reduction of 9.11:1 with a 95% confidence interval of 1.4:1 to 59:1. This level of support is 
above the threshold for moderate evidence (4.33:1 odds). We suggest that functional evidence 
supporting pathogenicity from HEK293 cells be used at the level of moderate. When the field 
generates additional data for control variants the weighting of PS3 for this assay should be 
reconsidered. 
While positive evidence (reduced EC50) is considered moderate support for pathogenicity, 
reduced penetrance and the limitations of expression systems,24 suggest a non-significant 
change in EC50 values may not support benign status at a moderate level. For that reason it was 
decided that lack of response to agonists be weighted as supporting evidence, BS3_Sup. 
Regarding other in vitro assays that test calcium release in response to agonists, where 
historical data were limited, we suggest that multiple controls be run in parallel and statistical 
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analysis be used to determine the level of strength for PS3 according to the Bayesian 
framework. Future data from control variants will allow for reconsideration of increased weight 
of PS3. 
In addition to in vitro assays, the RYR1/MH field has established ex vivo assays measuring 
calcium release in patient cells. These assays do not isolate the RYR1 variant from other 
potential variants (in RYR1, CACNA1S, or other MHS-associated genes), which may affect 
calcium release. Rather, these assays are a measure of the cellular phenotype in the patient. 
Although we recognize this limitation of ex vivo studies, we also recognize that they have utility. 
As the main concern for such assays is the potential presence of other variants, this concern is 
mitigated if multiple unrelated individuals with the same primary variant are shown to exhibit 
enhanced ex vivo sensitivity to agonist. Two unrelated individuals with ex vivo tests showing 
increased sensitivity of calcium release in response to agonist allow PS3_Sup. For variants 
where ≥3 unrelated individuals had ex vivo tests showing increased sensitivity of calcium 
release, PS3_Mod can be applied. Ex vivo tests that do not show increased sensitivity of calcium 
release in response to agonist (negative result) support a benign status of the variant. BS3_Sup 
can be applied if one or two unrelated individuals are tested with negative results, when ≥3 
unrelated individuals are tested and all results are negative BS3_Mod can be applied. 
Knock-in mouse models created to date to test RYR1 variants have shown MH reactions in 
response to exposure to volatile anesthetic and ex vivo studies of muscle samples from these 
mice show increased ligand sensitivity of calcium release as compared to WT.25-28 When knock-
in mice have an MH reaction in response to agonist, and where ex vivo studies show increased 
calcium release as compared to WT in response to agonist, PS3 can be awarded. For mouse 
	 13
models where either an MH crisis can be triggered by agonist or ex vivo assays show increased 
calcium release, but both conditions are not met, PS3_Mod is awarded. For mouse models that 
do not exhibit an MH reaction when exposed to agonist and ex vivo studies do not show 
increased release of calcium, BS3_Sup is can be awarded. 
Hotspot Specifications: PM1 
The ACMG/AMP criteria includes moderate weight for variation in critical protein domains or 
mutational hotspots, PM1. While critical domains may be well-defined for a protein, the 
concept of mutational hotspot is less clearly defined in the field. A general rule for 
consideration of a mutational hotspot would be an excess of pathogenic variation as compared 
to benign variation. In MH, variants have been noted to cluster in three regions of RYR1 
identified as “hotspots” historically: the N-terminal region (residues 1-552), the central region 
(residues 2,101-2,458) and the C-terminal region (4,631-4,991).29 Rather than defining clear 
functional domains, these regions are defined by an increase in variation identified in 
individuals with MH. We assessed this criterion using a test set of 21 variants (Table S3) 
assessed to be pathogenic for MH without the use of PM1 and 27 benign variants (Table S4) 
that met criteria BA1. This set of variants suggests a likelihood ratio for hotspots of 24:1 with a 
95% confidence interval of 3.5:1 to 166:1 (Table 2). This level of support is above the threshold 
for strong evidence (18.7:1 odds) and the lower bound of that confidence interval is above 
supporting (2.1:1). This would suggest that PM1 could be modified to PM1_strong. However, 
because there is a significant bias in the literature toward identifying pathogenic variants in the 
hotspots, to avoid the possibility of overestimating pathogenicity, we suggest instead using 
PM1 at its default level of moderate for variants in the N-terminal and central regions. We 
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suggest using PM1 at a supporting level for variants in the C-terminal region as variants in this 
region may be associated with CCD and not cause MH. Future studies that interrogate the gene 
without these biases should provide additional data on the positional skewing of pathogenic 
variants, which could allow us to upgrade this to strong in the future. 
Computational Evidence: PP3/BP4 
The PP3 and BP4 criteria consider computational evidence estimating the impact of a variant on 
protein function. REVEL is an ensemble method based on a number of individual tools and 
precomputed scores are available for all missense variants (https://omictools.com/revel-tool).12 
Importantly, REVEL does not consider population frequency, which reduces double counting of 
evidence. Using a set of 22 pathogenic determined to be pathogenic without the use of PP3 the 
and 27 benign variants described above, we tested the likelihood ratios of the predictive power 
of REVEL in several iterations. We settled on a trichotomization of scores with PP3, 
(computational evidence supporting pathogenicity), requiring a REVEL score of ≥0.85 and BP4, 
(computational evidence against pathogenicity), requiring a REVEL score of ≤0.5 (Table 3). 
These results suggest that PP3 and BP4 could be employed at the strong level. We chose to 
reduce PP3 to moderate as it was close to the Bayesian strong cutoff of 18.7:1 odds.13 Based on 
piloting these criteria it was determined that BP4 should be used at supporting and only 
implemented with other criteria. Using the Bayesian framework, BP4 in isolation results in an 
assessment of likely benign (LB) and it was determined that additional evidence should be 
available for a LB classification. For a fuller explanation of deriving such likelihood ratios, see 
Supplemental information. 
Piloting RYR1/MH Assessment Criteria 
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We applied these modified criteria to 44 variants EMHG determined to be “diagnostic 
mutations” and 40 RYR1 variants with pathogenicity assessments for MH in ClinVar. The 
classification of each of the variants is shown in Table S3 and Table S5. Four variants included in 
the EMHG variant list (https://www.emhg.org/diagnostic-mutations) were excluded from this 
assessment as they are not associated with MH. Of the remaining 44 EMHG variants, we 
assessed 30 to be pathogenic (P), 12 to be likely pathogenic (LP), and two to be variants of 
uncertain significance (VUS). Variant c.1589G>A p.(Arg530His) was assess as VUS and had 
limited functional data including a single ex vivo sample30, which did not meet PS3_Sup based 
on the requirement for a minimum of two unrelated individuals. Variant c.1598G>A 
p.(Arg533His) was assessed as VUS based on functional data (PS3_Mod) and presence in a 
hotspot (PM1). PS4 was not met by this variant based on a high allele count (32 alleles) in 
gnomAD. 
The revised criteria were applied to an 40 additional variants with pathogenicity assessments 
for MH in ClinVar. Ten variants had conflicting pathogenicity assessments for MH (pathogenicity 
assessments not indicated for MH were not considered), nine B/LB/VUS and one P/LP/VUS. Five 
variants with B/LB/VUS assessments in ClinVar were determined to be B/LB based on BA1/BS1. 
The remaining five discordant variants were assessed to be VUS. Of the remaining 30 variants, 
14 were reported as P/LP, 11 as B/LB and five as VUS. Applying the revised ACMG criteria 12/14 
variants with an assessment of P/LP in ClinVar and 3/11 variants with an assessment of B/LB in 
ClinVar were assessed as VUS. All variants assessed as B/LB (13) using our criteria had ether BA1 
or BS1 applied. The 19/24 variants assessed as VUS had limited data, only five VUS variants had 
data that refuted pathogenicity (5/24, 21%). 
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CONCLUSIONS 
As an expert panel within ClinGen, we set out to adapt the ACMG pathogenicity criteria for 
assessment of RYR1 variants as related to MH. Combining expertise of anesthesiologists, 
physiologists, biochemists, and geneticists allowed for a thorough evaluation of factors that 
should be considered. It is also important to recognize that we successfully unified the efforts 
of the American-based ACMG/AMP criteria with the extensive expertise and experience of the 
European Malignant Hyperthermia Group, benefiting from both. In revising these guidelines, 
we have considered the statistical evidence weight as it relates to the Bayesian adaptation of 
the ACMG scoring system. Weighting of evidence using statistical measures should allow for a 
more robust and consistent pathogenicity assessment framework. The revised RYR1/MHS 
specific criteria should allow clinical laboratories to more consistently assess these variants 
based on expert guidelines. These recommendations should be especially useful to laboratories 
that interpret RYR1 variants as secondary findings in exome and genome sequencing. That MH 
is a pharmacogenetic trait with relatively low penetrance makes it especially challenging to 
interpret for laboratories that do not peform a high volume of diagnostic RYR1 testing. The 
availability of these three star ClinGen interpretations should significantly reduce the amount of 
time that these secondary findings evaluations consume and should increase the consistency of 
the interpretations, as has been demonstrated for the generic ACMG/AMP pathogenicity 
recommendations.31 As well, the RYR1/MH expert panel will continue to curate variants and 
deposit assessments into ClinVar. Standardized ClinVar assessments will be useful to 
laboratories identifying variants as secondary findings that may not have RYR1/MH expertise. 
Moving forward, the field should strive to increase relevant data through functional studies and 
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shared case documentation allowing variants to move from an assessment of VUS to either 
LB/B or LP/P. Beyond secondary findings, ClinGen interpretations of RYR1 variant pathogenicity 
will allow the field to consider pre-surgicial screening of patients toward elimination of MH 
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Table 1. Modified ACMG criteria suggested for RYR1/MH. 
Criteria Criteria Description Specification 
VERY STRONG CRITERIA 
PS2/PM6_Very Strong Each proven de novo case, 2 points, each assumed de novo case, 1 point, ≥8 points Strengtha 
STRONG CRITERIA 
PS1 Same amino acid change as a previously established pathogenic variant regardless of nucleotide change 
• Previously established pathogenic variant must reach a classification of pathogenic without PS1 
None 
PS2/PM6_Strong Each proven de novo case, 2 points, each assumed de novo case, 1 point, a total of 4-7 points Strengtha 
PS3 Well-established functional studies supportive of a damaging effect on protein function 
• Knock-in mouse showing MH reaction in response to RYR1 agonist AND increased sensitivity to RYR1 
agonists in ex vivo tissue/cells 
Strengtha, Disease-
Specific 
PS4 The prevalence of the variant in affected individuals significantly increased compared with the prevalence in 
controls 
• ≥7 MH case points. Probands with a personal or family history of an MH event are awarded 0.5 points, 
probands with a personal or family historyb of a positive (MHS) IVCT/CHCT are awarded an additional 0.5 
points. Popmax in gnomAD ≤0.00006 
• For variants with popmax MAF gnomAD >0.00006, an odds ratio of ≥18.7 when comparing MH case 
points to allele count in gnomAD can qualify.  Popmax in gnomAD must be <0.0038 
Strengtha, Disease-
Specific 
PP1_Strong • Co-segregation with disease in ≥7 reported meioses Strengtha 
MODERATE CRITERIA 
PM1 Located in a mutational hot spot and/or critical and well established functional domain 
• Residues 1-552 (N-terminal region) and 2,101-2,458 (central region) 
Disease-Specific 
PM5 Missense change at an amino acid residue where a different missense varaint previously determined to be 
pathogenic 
• Previously established pathogenic variant must reach a classification of pathogenicity without PM5 
• Grantham score for alternate pathogenic variant must be less than for variant being assessed 
None 
PS2/PM6_Moderate Each proven de novo case, 2 points, each assumed de novo case, 1 point, a total of 2-3 points Strengtha 
PS3_Moderate Well-established functional studies supportive of a damaging effect on protein function 
• Increased sensitivity to RYR1 agonist in HEK293 in vitro assay, Ca2+ release significantly increased 
compared to WT, controls to include known pathogenic and benign variants, n≥3. 
• Three or more independent ex vivo studies all showing release of Ca2+ in response to RYR1 agonist 
• Knock-in mouse showing MH reaction in response to RYR1 agonist OR increased sensitivity to RYR1 




PS4_Moderate The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in 
controls 
• 2-6 MH case points.  Probands with a personal or family historyb of an MH event are awarded 0.5 points, 
probands with a personal or family history of a positive (MHS) IVCT/CHCT are awarded an additional 0.5 
points. Popmax in gnomAD ≤0.00006 
• For variants with popmax MAF in gnomAD >0.00006, an odds ratio of ≥4.33 when comparing MH case 
points to allele count in gnomAD can qualify.  Popmax in gnomAD must be <0.0038 
Strengtha, Disease-
Specific 
PP1_Moderate • Co-segregation with disease in 5-6 reported meioses Strengtha 
PP3_Moderate Multiple lines of computational evidence support a deleterious effect on the gene or gene product 
• Use REVEL score of ≥0.85 
Strengtha 
SUPPORTING CRITERIA 
PP1 Co-segregation with disease in 3-4 reported meioses Strengtha 
PS2/PM6_Supporting Each proven de novo case, 2 points, each assumed de novo case, 1 point, a total of 1 point Strengtha 
PS3_Supporting Well-established functional studies studies supportive of a damaging effect on protein function 
• Two independent ex vivo studies all showing release of Ca2+ in response to RYR1 agonist 
Strengtha, Disease-
Specific 
PS4_Supporting The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in 
controls 
• 1  MH case point.  Probands with a personal or family historyb of an MH event are awarded 0.5 points, 
probands with a personal or family history of a positive (MHS) IVCT/CHCT are awarded an additional 0.5 
points. Popmax in gnomAD ≤0.00006 
For variants with popmax MAF in gnomAD >0.00006, an odds ratio of ≥2.08 when comparing MH case points 
to allele count in gnomAD can qualify.  Popmax in gnomAD must be <0.0038 
Strengtha, Disease-
Specific 
PM1_Supporting Located in a mutational hot spot and/or critical and well established functional domain 




STAND ALONE CRITERIA 
BA1 Popmax allele frequency >0.0038 (0.38%) Disease-Specific 
STRONG CRITERIA 
BS1 Popmax allele frequency >0.0008 (0.08%) Disease-Specific 
BS2 Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked 
(hemizygous) disorder with full penetrance expected at an early age. 
• Two or more variant positive indviduals with a negative IVCT/CHCT test 
Disease-Specific 
MODERATE CRITERIA 
BS2_Moderate Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked 
(hemizygous) disorder with full penetrance expected at an early age. 





BS3_Moderate Well-established functional studies show no damaging effect on protein function 




BP2 Observed in cis with a pathogenic variant in any inheritance pattern None 
BP4 Computational evidence suggest no impact on gene or gene product, REVEL score of ≤0.5  None 
BP7 A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice 
consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved 
None 
BS3_Supporting Well-established functional studies studies show no damaging effect on protein function 
• No significant increased sensitivity to RYR1 agonist in an approved in vitro assay, Ca2+ release measured, 
n≥3 
• One or two independent ex vivo studies, NO significant release of Ca2+ in response to agonist 
• Knock-in mouse showing no MH reaction in response to RYR1 agonist AND no increased sensitivity to 
RYR1 agonists in ex vivo tissue/cells 
Strengtha, Disease-
Specific 
Key: Disease-Specific, Disease-specific modifications based on what is known about MHS; Strength, Increasing or decreasing strength of criteria based on the 
amount of evidence; N/A: not applicable for MHS; None, no changes made to existing criteria definitions; IVCT, in vitro contracture test; CHCT, caffeine-
halothane contracture test. 
aFor criteria that can be assigned different levels of strength based on evidence, only the highest applicable strength level should be used. For example, if 
PS4/PM2_Strong is met, then PS4/PM2_Moderate and PS4/PM2_Supporting are not used. 
bPositive family history defined by variant positive family member with MH reaction and/or positive IVCT/CHCT. 
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Table 2. Distribution of 21 pathogenic and 27 benign variants in relation to position of 
defined RYR1/MH hotspots. Likelihood ratios calculated based on distribution. 
Presence in 
HotSpot 




18 1a 24.00  3.48-165.77 
Non-HotSpot 3 27 0.148 6.76 0.05-0.42 
aNo benign variants were identified in the hotspot regions, for calculation of LR we used 
a value of 1.  
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Table 3. REVEL score distribution for 22 pathogenic and 27 benign variants for 
RYR1/MH. Likelihood ratio for separation of pathogenic and benign variants based on 
REVEL scores using cutoff values of >0.85 and <0.5. 
REVEL 
score 
Pathogenic Benign Likelihood 
ratio (LR) 
Inverse LR 95% CI 
>0.85 19 1a 23.13  3.35-159.96 
0.5-0.85 3 8 0.46 2.19 0.14-1.53 
<0.5 1a 19 0.06 15.63 0.01-0.44 
aNo benign variants were identified with a REVEL score >0.85 and no pathogenic 
variants were identified with a REVEL score <0.5, for calculation of LR we used a value of 
1.	 	
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Figure 1. Cumulative HEK293 transfection assay data for RYR1 variants from the 
literature. Variants are grouped according to pathogenicity assessment without 
consideration of PS3/BS3 (functional data). 
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Figure 2. 
